Articles related to NON-HODGKIN LYMPHOMA (NHL)

Tafasitamab plus lenalidomide added to R-CHOP reduced the risk of progression or death by 25% compared with R-CHOP alone in previously untreated high-risk DLBCL and HGBL in a 899-patient phase 3 trial, with overall survival data not yet mature.

Ipsen voluntarily withdrew tazemetostat in follicular lymphoma and epithelioid sarcoma after 18 of 318 SYMPHONY-1 participants developed hematologic second primary malignancies, including three deaths.

“Although historically grouped together, viral-associated PCNSL subtypes are biologically distinct diseases. Each escapes immune control through a different mechanism, creating fundamentally different tumor microenvironments.” – Melinda Burgess, Researcher from the Department of Haematology at Princess Alexandra Hospital

The recent study on MCL reveals a promising approach in identifying high-risk patients through the combination of MIPI-c and p53 overexpression. This method may guide the development of targeted therapies and personalized treatment plans, addressing the unmet needs of those at the highest risk.

Explore how the recent FDA approval of Epkinly is poised to transform the therapeutic landscape for adults with relapsed or refractory DLBCL and high-grade B-cell lymphoma.

Judith Trotman, MBChB, FRACP, FRCPA, clinical professor at the University of Sydney in Concord, New South Wales, Australia, and head of the Hematology Department at Concord Repatriation General Hospital, provides background on mantle cell lymphoma, its unique treatment challenges, and the significance of the SHINE trial, which assessed ibrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma.